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ABSTRACT
Introduction: The aim of this study was to
assess the total frequency of self-treated
hypoglycemia in type 2 diabetes mellitus
patients using regimens including basal insulin
analogs, and to describe the psychological
impact and behavioral response to these
events from the perspective of patients and
prescribers (i.e., hospital specialists and primary
care physicians).
Methods: The global attitude of patients and
physicians 2 (GAPP2) survey was an online
multinational, cross-sectional survey of patients
with type 2 diabetes mellitus treated with basal
insulin analogs, with or without bolus insulin.
Prescribers directly involved in the care of these
patients were also surveyed. Here, we report the
results of the second wave of the GAPP2 survey,
in which the primary variable of interest was
self-treated hypoglycemia.
Results: A total of 855 patients and 1003
prescribers, from 7 countries, completed the
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survey. Overall, 28% of patients had
experienced self-treated hypoglycemia during
the previous 30 days, with two-thirds of events
occurring during the day and one-third of
events occurring nocturnally. Prescribers
reported discussing events with 55% of
patients over this period. Patients worried
about self-treated hypoglycemia in a range of
situations, and prescribers under-estimated this
worry. Many patients who had experienced
self-treated hypoglycemia in the last 30 days
reported missing (19%), mistiming (7%), or
reducing (7%) their basal insulin dose as a
result.
Conclusion: Self-treated hypoglycemia was
relatively common in patients using basal
insulin analogs, with or without bolus insulin.
Whilst the frequency of hypoglycemia was
greater during the daytime than at night,
patients worried more about nocturnal events
and this level of worry was under-estimated by
physicians. Additional advice and support may
be needed for both patients and prescribers, to
reduce the frequency and impact of self-treated
hypoglycemia.
Funding: Novo Nordisk.




The use of insulin to reduce blood glucose levels
in type 2 diabetes mellitus (T2DM) is highly
effective, but can be challenging (e.g., taking
time to develop an appropriate regimen) and
the risk of hypoglycemia remains an important
consideration for both physicians and patients
[1–3].
Severe hypoglycemia, defined as an event
requiring the assistance of another person to
actively administer carbohydrates, glucagon, or
take other corrective actions, is a key cause of
morbidity in T2DM and an important barrier to
optimal glycemic control [4]. Less severe
hypoglycemic events that the individual can
self-treat by consuming fast-acting
carbohydrate, known as ‘self-treated’ or
‘minor’ hypoglycemic events, are not always
recognized by the individual or their clinical
team as being clinically significant. Data suggest
that self-treated hypoglycemic events, whether
they occur in the daytime or at night, have an
impact on patient functioning, well-being and
diabetes management [5–7]. Of particular
importance is the relationship between, often
unnoticed, nocturnal hypoglycemia and poor
health outcomes including adverse
cardiovascular events [8]. Self-treated
hypoglycemia also has substantial economic
consequences for patients and their employers
due to lost working hours and reduced
productivity [7]. Recently, reported data from
Denmark suggest that 9% of self-treated
episodes lead to lost work time [9]. In the UK,
self-treated hypoglycemia is estimated to cost
the National Health Service £172.1 million per
year [10]. Recent research in the USA found that
non-severe episodes incur a cost of $11 per
episode [11].
Research has also suggested that around
one-third of patients are very worried about
hypoglycemia, and a similar proportion
maintain their blood glucose levels within a
‘safety margin’ at levels above recommended
targets, in an attempt to reduce the risk of
hypoglycemia [8]. Given the important effect of
these events on both patient functioning and
diabetes management, the prevalence and
impact of self-treated hypoglycemic events
among patients with T2DM requires additional
study. For this reason, the Global Attitude of
Patients and Physicians 2 (GAPP2) web-based
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survey was initiated. The first wave of the online
survey was initially conducted among patients
treated with basal or basal plus bolus insulin
analogs and relevant prescribers (i.e., hospital
specialists and primary care physicians) in six
countries: Canada, Denmark, Germany, Japan,
UK, and USA. One of the key aims of the first
wave was to estimate the prevalence of
self-treated hypoglycemia in patients and
identify demographic, treatment-related and
behavioral risk factors associated with these
events. The key findings from the first wave of
the survey have been published elsewhere [3, 6,
12, 13].
In wave two, reported here, the survey was
extended to further countries in Europe, North
and South America, Asia, Africa, and Australia.
Similar to the first wave, the primary aim was to
collect and assess data regarding self-treated
hypoglycemia in users of basal insulin analogs,
with or without bolus insulin, from both the
patient and prescriber’s perspective.
METHODS
Recruitment
All procedures conducted were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Informed consent was obtained from all patients
included in the survey. Data were collected
between September 2012 and January 2013. In
total, 11 countries were included in the second
wave of the survey. This manuscript focuses on
pooled data from seven countries: Argentina,
Australia, India, Israel, Mexico, Russia, and South
Africa. Data from these countries were pooled as
they belonged to the region of international
operations of the study sponsor.
Patient participants were recruited from
online general population research panels,
using recruitment techniques representative of
the local online community including banner
advertisements, e-mail campaigns, blogs, social
media, TV/print and SMS campaigns. Patient
eligibility criteria required being diagnosed with
T2DM over the age of 40 years and being on a
long-acting basal insulin analog alone, or on
long-acting basal and short-acting bolus insulin
analogs taken separately. To maintain
consistency and enable comparison with the
results from the first wave of the GAPP2 survey,
patients on bolus only, premix insulin or using
insulin pumps were excluded [3, 6, 12, 13].
Prescribers were recruited from pre-existing
online healthcare professional research panels
and were initially targeted by specialty (i.e.,
primary care, specialist, or other). They were
then screened to ensure that they treated a
minimum number of patients with diabetes in a
typical month. Criteria varied by country, but
typically 20 patients per month for general
practitioners (GPs) and 40 patients per month
for hospital specialists were sufficient for
inclusion.
Survey
The survey materials have previously been
described in greater detail in the first wave of
the GAPP2 survey [3, 6, 12, 13]. Survey items
were generated from multiple data sources: an
international steering committee of diabetes
clinical experts, relevant current literature, and
from key concepts and themes from the
transcripts of nine previously conducted focus
groups and interviews with patients with
diabetes. Questionnaires for both patients (90
items) and physicians (58 items) were
structured in the same way to facilitate
between-group comparisons. Items covered
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demographics and background information,
diabetes management, self-treated
hypoglycemia and patient functioning and
well-being. Self-treated hypoglycemic events
(i.e., ‘hypos’) were defined as symptoms of low
blood sugar (i.e., sweating, weakness, trembling
or difficulty concentrating) that patients could
treat by themselves by drinking a glass of juice,
eating, or taking a sugar pill. Patients were
specifically asked about the characteristics,
incidence and impact of such events, with
physicians being asked to answer all questions
by thinking about their own patients who were
prescribed basal insulin analogs, with or
without bolus insulin.
To minimize any recall bias on patient
responses, participants were asked to only
report events that occurred during the 30 days
prior to completion of the survey. Participants
were offered an ‘‘I don’t know’’ answer where
applicable to avoid forcing inaccurate
responses, and all data were logic-tested to
ensure that participants did not provide
contradictory answers. Data identified
electronically as being incomplete were
collected but not processed or included in the
analyses.
Statistical Analysis
Statistical analysis was conducted using
statistical analysis software SAS (SAS Institute
Inc., Cary, NC, USA). To describe the patient
and prescriber population, the data were
descriptively analyzed using frequencies and
mean values. Paired t tests were used to show
the actual differences between groups where
applicable. Pearson’s Chi squared test was used
for non-parametric data. Outliers were
identified by taking a range from either the
mean or median score, depending on the
question type. Where notable numbers of
outliers were seen to be affecting the results
for a given question, the question was assessed
subjectively and responses outside the
statistically acceptable range deemed not




A total of 509,692 participants were invited to
participate in the survey and 2271 prescribers
and 15,180 patients responded. Of these, 855
patients and 1003 prescribers were eligible for
and completed the survey (Fig. 1). The mean
age of the patient sample was 57.1 years, with a
mean diabetes duration of 8.2 years. The
prescriber sample treated a mean of 127.7
patients aged [40 years per month. Table 1
summarizes the full characteristics of the
sample.
Total Frequency of Self-Treated
Hypoglycemia
For the sample as a whole, 28% of respondents
reported that their last event was during the last
30 days and the mean number of events per
patient was 3.8 per month. For daytime
self-treated hypos, the mean number of events
per patient was 2.6 per month. For nocturnal
self-treated hypos, the mean number of events
per patient was 1.3 per month (Table 2).
Discussion of Self-Treated Hypoglycemia
Totals of 59% and 42% of all respondents
reported that self-treated hypos were typically
discussed during consultations with specialists
and GPs, respectively. Prescribers reported that
they had only discussed or reviewed minor
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hypos with 55% of the patients that they had
seen in the past 30 days. When prescribers were
asked to describe how often they discussed
minor hypos with these patients, only 57%
said they ‘always’ or ‘most of the time’ discussed
with patients on basal only insulin and 69%
said they ‘always’ or ‘most of the time’ discussed
with patients on basal–bolus insulin (Fig. 2).
Prescribers were asked why they chose not to
discuss minor hypos with some of these
patients. With basal only patients, the most
commonly cited reasons were: patients are
already well educated about minor hypos
(72%); patients do not report minor hypos
(44%); and a lack of time during consultation
(29%). When asked about basal–bolus patients,
the same three responses were reported (67%,
34%, and 31%, respectively). Prescribers also
estimated that about one-quarter of their
patients under-reported the frequency (31%)
or severity (24%) of minor hypos they had
experienced.
Impact of Self-Treated Hypoglycemia
Patients were asked how long it took to perceive
that they had regained normal physical and
mental functioning after a self-treated hypo.
The time to recover physical and mental
functioning was believed by 32% and 45% of
patients, respectively, to be longer than 1 h. For
prescribers, 25% reported that they believed it
took their patients longer than 1 h to recover
normal physical functioning and 43% reported
they believed it took their patients longer than
1 h to regain mental functioning. Areas of
functioning that patients felt were particularly
affected by self-treated hypos were
‘performance at work’, ‘ability to focus and
concentrate,’ and ‘taking part in sport and
Fig. 1 Patient and prescriber survey recruitment ﬂow diagram. HCP healthcare professional
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exercise’ (47%, 45%, and 45% of patients,
respectively, reporting a ‘significant’ or
‘somewhat’ negative impact).
Levels of Worry About Self-Treated
Hypoglycemia
Patients worried about self-treated hypos in a
wide variety of circumstances: more than
two-thirds of patients admitted to being ‘very’
or ‘somewhat’ worried about events during each
of the following daily situations: ‘somewhere
where there is no easy access to food or drink’
(75% of patients), ‘when driving’ (70%), ‘while
sleeping’ (68%), ‘when alone at home’ (68%),
and ‘while caring for children/grandchildren’
(68%). Patients also stated that they were more
likely to worry about nocturnal self-treated
hypos than daytime events: 68% versus 57%,
respectively, reported they were ‘very’ or
‘somewhat worried’.
Prescribers appeared to underestimate this
worry; for each of the five daily scenarios
described above, fewer than 30% of prescribers
felt that their patients worried about minor
hypos: ‘while sleeping’ (29%), ‘when alone at
home’ (19%), ‘when driving’ (19%),
‘somewhere where there is no easy access to
food or drink’ (18%), and ‘while caring for
children/grandchildren’ (12%).
When prescribers were asked to state the
situation in which they felt their patients
worried the most about minor hypos, the most
common response was ‘whilst sleeping’ (Fig. 3).
However, half of prescribers reported that they
believed that less than 25% of their patients
worried about nocturnal minor hypos.
Response to Self-Treated Hypoglycemia
A substantial proportion of patients reported
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response to self-treated hypos. Among patients
who had ever experienced such an event, 19%,
15%, and 13%, respectively, reported that they
responded by missing, mistiming ([2 h earlier
or later than prescribed), or reducing a dose of
their basal insulin. Among patients who had
experienced such an event in the past 30 days,
19% (range 1–30 occasions), 7% (range 1–30
Table 2 Frequency of self-treated hypoglycemia among patients in the last 30 days
Total
sample
Argentina Mexico India Australia Israel Russia South
Africa
Effective base (n) 776 86 143 145 108 68 163 63
% of patients with at
least one event (n)
28% (217) 31% (27) 47% (67) 14% (21) 33% (36) 29% (20) 25% (40) 10% (6)
All self-treated
hypoglycemia*
Mean number of events
per patient (range)
3.8 (1–25) 5.0 (1–15) 3.3 (1–10) 4.5 (1–12) 3.2 (1–20 3.1 (1–20) 4.1 (1–25) 6.8 (1–23)
% of patients with
5 ? events (n)
25% (55) 52% (14) 22% (15) 29% (6) 17% (6) 20% (4) 18% (7) 50% (3)
Daytime self-treated
hypoglycemia*
Mean number of events
per patient (range)
2.6 (0–25) 2.9 (0–10) 2.0 (0–8) 2.5 (0–6) 2.8 (0–20) 2.0 (0–10) 3.0 (0–25) 5.5 (1–20)
% of patients with
5 ? events (n)
13% (29) 26% (7) 9% (6) 5% (1) 14% (5) 20% (4) 13% (5) 17% (1)
Nocturnal self-treated
hypoglycemia*
Mean number of events
per patient (range)
1.3 (0–10) 2.1 (0–7) 1.3 (0–5) 2.0 (1–8) 0.4 (0–3) 1.1 (0–10) 1.1 (0–6) 1.3 (0–3)
% of patients with
5? events (n)
6% (12) 19% (5) 3% (2) 14% (3) 0% (0) 5% (1) 3% (1) 0% (0)
* Among patients who had experienced at least one episode of self-treated hypoglycemia (daytime or nocturnal) in the last 30 days
Fig. 2 Frequency with which prescribers discuss minor hypoglycemia with their patients
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occasions), and 7% (range 1–30 occasions),
respectively, reported missing, mistiming, or
reducing a dose of their basal insulin in
response. On average, around 25% of patients
reported increasing the frequency of blood
glucose monitoring in response to self-treated
hypos (Fig. 4).
A fear of nocturnal hypos appeared to be a
particularly common reason for insulin
misdosing. A total of 22% of patients reported
that they had intentionally let their blood sugar
level go higher than it should to reduce the risk
of nocturnal self-treated hypos. A similar
proportion (22%) reported that they had, at
some time, not taken their insulin exactly as
prescribed due to fear of nocturnal hypos.
Prescribers were asked to describe the
recommendations they gave to patients who
experienced a number of minor hypos. The
actions that most physicians reported they
undertook ‘most or all of the time’ were
educational: ‘educate the patient on how to
avoid hypoglycemia’ (80% of prescribers),
‘educate the patient on how to recognize
hypoglycemia’ (79%), and ‘advise them on
how to self-manage hypoglycemia’ (77%).
Prescribers reported they were likely to adjust
the treatment regimen ‘most or all of the time’
in such cases: ‘reduce the dose of basal insulin
temporarily until they have restored
hypoglycemia awareness’ (23%), ‘reduce the
dose of basal insulin long-term’ (14%), ‘split
the basal insulin into two doses’ (4%), ‘switch
the type of insulin they are on’ (3%).
Self-treated hypos were also found to have
an impact on healthcare resources; many
patients who had experienced a self-treated
hypo reported making unplanned trips to a
diabetes specialist (26%), a primary healthcare
provider (25%), or a hospital emergency
department (14%). Further, a majority of
prescribers (58%) reported that they were
contacted at least once per month as a result
of a patient experiencing a minor hypo, while
15% reported that they were contacted at least
once per week.
Fig. 3 Situations in which prescribers feel their patients with type 2 diabetes on insulin analogs worry most about
self-treated hypoglycemia
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DISCUSSION
This manuscript reports data from the second
wave of the GAPP2 survey, which specifically
examined the cumulative prevalence and
impact of self-treated hypos among patients
with T2DM treated with basal insulin analogs,
with or without bolus insulin. The results
corroborate many of the findings from the first
wave of the GAPP2 survey [3, 6, 12, 13]. With
regard to the incidence of self-treated hypos
(i.e., missing, mistiming, or reducing doses),
28% of patients reported that they had
experienced an event in the last 30 days.
While this is lower than the 36% of patients
who reported events in the first wave, it
confirms that self-treated hypos are still
relatively common in the lives of those with
T2DM who are receiving treatment with insulin
analogs.
Similar patterns of behavior in response to
self-treated hypos were reported in the current
survey and in the first wave, but a notably
higher incidence of missed doses was observed
in the current survey compared with the first
wave (i.e., 19% versus 7%, respectively). The
causes of this higher incidence observed in the
second wave countries require further research.
As in the first wave, we observed a higher rate of
worry regarding nocturnal hypos compared
with daytime events [3]. It is of note that the
seven countries represented in the current
survey differ substantially from those
providing data in the first wave in terms of
their culture, health systems and economics. It
is therefore of interest that the psychological
and behavioral findings from the current survey
align with those of the more homogenous first
wave cohort. This suggests that responses to
self-treated hypos are not culture-specific and
can be generalized worldwide.
Research has suggested that as few as 10
symptomatic, non-severe hypos per year can
have a clinically relevant impact on functioning
Fig. 4 Frequency of speciﬁc responses to self-treated hypoglycemia (ever experienced and last 30 days) among patients on
basal insulin analogs
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(e.g., work productivity). Further, the
psychological impact of these events increases
with their frequency [14, 15]. Extrapolation of
the mean number of minor self-treated hypos
observed in the current survey (i.e., 3.8 events
over 30 days) suggests that many patients could
be experiencing more than 40 self-treated hypos
per year. Moreover, almost half of patients and
physicians felt that the time taken to recover
normal mental functioning after a minor hypo
was greater than one hour, highlighting the
non-trivial impact that these events can have
on daily functioning. Hence, these results
would indicate there is a need for enhanced
surveillance and greater patient education when
consulting with individuals at higher risk for
minor hypos.
The results also indicate that prescribers
greatly under-estimated levels of concern
among their patients with regard to
self-treated minor hypos. For example, while
75% of patients reported that they worried
about self-treated hypos in situations where
there was no easy access to food or drink, only
18% of physicians felt that patients worried
about this scenario. This discrepancy suggests
that prescribers may need to adopt a more
proactive approach to addressing and managing
their patients’ concerns regarding
hypoglycemia, particularly with patients who
have recently experienced a minor hypo, as
these individuals often experience a greater fear
of future events [16, 17].
Further, the impact of these events on
general diabetes management must be
considered. For some patients it may be
necessary to adjust clinical management to
account for their behavioral and psychological
responses to events, since these responses
include reducing or missing insulin doses and
deliberately allowing blood glucose levels to
rise. It is noteworthy that more than
three-quarters of prescribers reported that they
would usually respond to a patient experiencing
repeated minor hypos by educating them on
recognizing/avoiding and self-managing such
events. However, few prescribers reported they
would typically adjust the treatment regimen
(e.g., switching the type of insulin or reducing
the basal insulin dose temporarily or
long-term). Such adjustments may be clinically
appropriate in some cases, and it is important
that prescribers remain vigilant to the potential
threat of minor hypos. In this survey,
prescribers reported that they had discussed
minor hypos with only half of the patients they
had seen in the past 30 days. It is thus likely that
a greater focus on discussing minor hypos at
initiation and/or early in insulin treatment
could help to reduce the frequency of these
events.
The survey had a number of important
limitations that should be discussed. To enable
comparison with the first wave of the GAPP2
survey [3, 6, 12, 13], we employed the same
web-based methodology and this could be
argued to have produced a selection bias.
Namely, only literate participants with
internet access were able to participate and it
is likely that internet accessibility varied
between the different countries that were
sampled. This may have resulted in local
over-representations of specific demographic
groups with internet access, such as younger
patients and those in office-based
employment—particularly in developing
countries where internet access is more
limited. As an example, the Indian sample was
more than 10 years younger and more than
twice as likely to be employed when compared
with the Australian sample. Moreover, internet
access may still be an indicator of
socioeconomic status and access to quality
medical care, including the availability of
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prescription medication. Overall, these factors
would suggest that the survey participants were
not fully representative of the insulin-treated
diabetes population in their respective
countries.
Consequently, future research is now needed
to survey more representative cohorts through
the use of alternative methods (e.g., face-to-face
interviews) and the inclusion of different
insulin regimens (e.g., insulin pump therapy
and premix insulin). For instance, in India,
premix insulin is the preferred insulin
treatment for T2DM, and the frequency and
impact of self-treated hypos within this patient
group is of clinical interest. As this survey was
not designed to examine country-specific
differences, further research is also needed to
better understand the potential influence of
culture and healthcare systems on the
frequency of minor events, along with their
psychological and behavioral outcomes. We
also did not include a baseline measure of
HbA1c, which would have allowed for the
relationship between level of glycemic control,
frequency and impact of self-treated hypos to be
examined.
In addition, the survey was self-reported,
which may have led to systematic errors (e.g.,
recall bias) that affected the accuracy of the
responses. Attempts were made to mitigate this
by focusing on self-treated minor hypos from
the past 30 days only, and previous surveys and
findings from focus groups conducted prior to
GAPP2 have concluded that the recall of hypos
can be accurate for up to one month [7, 18].
Additionally, an unwillingness to admit to
negative outcomes (i.e., social desirability
bias) may have led some respondents to
under-report hypos. For instance, a
conscientious patient diagnosed with T2DM
may view high rates of minor hypos as an
indication that they are not adequately
managing their illness. To reduce the
likelihood of this, patients were informed that
results were confidential and that their data
would not be shared with their physician.
CONCLUSIONS
It is clear from the findings in the present,
second wave of the GAPP2 survey that many
patients with T2DM using basal insulin analogs,
with or without bolus insulin, need additional
advice and support to further reduce rates of
self-treated hypoglycemia. The current
consensus statement from a working group of
the American Diabetes Association and the
Endocrine Society describes a number of
strategies that are known to help prevent
hypoglycemia [4]. These include patient
education, dietary intervention, exercise
management, medication adjustment, glucose
monitoring, and clinical surveillance. Each of
these approaches is potentially valid for
managing both minor and severe
hypoglycemia. During consultations with
health professionals, all patients should be
proactively approached on the topic of
hypoglycemia to help mitigate the risk of such
events occurring. An important clinical
consideration is also the regular measurement
of markers of over-insulinization, such as
weight gain.
Our findings therefore support the need for
implementation of the strategies outlined in the
consensus statement. Additional research is also
required to further characterize the attributes of
patients at risk for minor hypoglycemia,
including personality, culture, glucose control,
complexity of insulin regimen, and lifestyle
factors. It will then remain to be determined
how these factors may predict the psychological
and behavioral responses observed in the
current survey.
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